Salvia Cures Addiction

We are hearing and reading more and more story's about Salvia curing addiction. Addiction of Crack, Cocaine, Nicotine and more. We firmly believe medicinal salvia can become the key to curing addiction. Not only can salvia cure addiction but it can also help with anxiety and arthritis. Many people firmly believe salvia helps arthritis, and it is much cheaper than pharmaceutical drugs. If you have anything to add.. please email the host of this site.

 

Here are a couple of interesting articles we came across:

 

Opioid receptor types and dependence
by
Suzuki T; Misawa M
Department of Pharmacology,
School of Pharmacy,
Hoshi University, Tokyo, Japan.
Nippon Yakurigaku Zasshi, 1997 Apr, 109:4, 165-74

ABSTRACT

The existence of mu, delta and kappa opioid receptors in the central nervous system is well documented. The present review focuses on the relationships between opioid receptor types and physical and psychic dependences. Mu and delta, but not kappa opioid receptor agonists produce physical dependence. From behavioral, biochemical and molecular biological studies, it is suggested so far that development of physical dependence on morphine results predominantly from an activation of mu 1 and mu 2 opioid receptors which causes functional changes in Gi/o, adenylate cyclase, protein kinases A and C, beta-adrenoceptor and NMDA receptor in the locus coeruleus. Recently, there have been significant advances in studies on psychic dependence. Mu and delta opioid receptor agonists produce psychic dependence, but kappa opioid receptor agonists rather produce an aversive effect. Activation of the mesolimbic dopamine system may lead to psychic dependence on opioids. Mu and delta 1 opioid receptor agonists activate the mesolimbic dopamine system to induce a rewarding effect, whereas the rewarding effect of delta 2 opioid receptor agonists may be produced through a non-dopaminergic system. There are complicated interactions among opioid receptor types. The activation of kappa opioid receptor suppresses physical and psychic dependences on mu and delta opioid receptor agonists, but the activation of delta opioid receptor potentiates the dependence on mu opioid receptor agonists. The clinical use of morphine in patients with cancer pain won't develop dependence probably due to the balance of the opioid system coming from these interactions.

 

An open-label study of a functional opioid kappa
antagonist in the treatment of opioid dependence
by
Rothman RB, Gorelick DA, Heishman SJ,
Eichmiller PR, Hill BH, Norbeck J, Liberto JG
National Institute on Drug Abuse,
National Institutes of Health,
5500 Nathan Shock Drive, Baltimore, MD, USA.
J Subst Abuse Treat 2000 Apr; 18(3):277-81

ABSTRACT

Several lines of evidence, including the well-established observation that kappa opiate agonists produce dysphoria and psychotomimetic effects in humans, suggest that dysfunction of the endogenous kappa opioid system may contribute to opioid and cocaine addiction. The objective of this open-label study was to determine the effectiveness of a functional kappa antagonist as a treatment for opioid dependence. This was accomplished by combining a partial mu agonist/kappa antagonist (buprenorphine, 4 mg, sublingual) with a mu antagonist (naltrexone, 50 mg by mouth), theoretically leaving kappa antagonism as the major medication effect. Subjects were treatment-seeking heroin-dependent (as per Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) men (41 +/- 7 years old; 19 +/- 8 years heroin use) eligible for methadone maintenance. After inpatient detoxification and a naloxone-challenge test to verify that they were not physically dependent on opioids, subjects received naltrexone. Starting on the fourth day, patients also received liquid buprenorphine. All patients received medication at the clinic 6 days per week and a full program of psychosocial treatment. The major endpoints of the study were: pupil diameter to determine if the &mgr; agonist effects of buprenorphine were blocked by naltrexone, urine toxicology, and retention in treatment. Five patients (33%) completed the 3-month study. Four were abstinent from opioids and cocaine for the entire study, and one was abstinent from opioids and cocaine for the last 9 weeks. Six subjects dropped out due to either minor side effects or disliking the sensation of sublingual buprenorphine. There were no significant changes in pupillary diameter. The positive response to treatment exceeds that expected from naltrexone alone (90% dropout). These promising results suggest that controlled studies of this medication combination should be conducted.

Medicinal Salvia Divinorum is constantly being tested to serve as a possible life saver to people struggling from addiction to life threatening drugs. Please let us know if you have more information on this topic.